Year: 2025
Type: article
Abstract: Type 1 diabetes (T1D) is an autoimmune disease characterized by destruction of insulin-producing beta cells in the pancreas. Early intervention with teplizumab-mzwv (brand name Tzield) can be considered to delay the need for insulin therapy for patients with Stage 2 T1D ≥8 years of age. Eligibility requires the presence of at least two islet autoantibodies in addition to evidence of dysglycemia, but without meeting Stage 3 T1D glycemic criteria. Clinical practice and experience with this treatment is expanding; however, approval, access, administration, and subsequent monitoring practices remain variable in general practice. Here we present a brief discussion regarding our experience with teplizumab-mzwv at the Riley Hospital for Children at Indiana University Health.
DOI: 10.69734/59hkbn82
Authors: Jamie L. Felton, Alex Tuttle, Emily K. Sims
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W4410927965